- ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF
-
The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.
- -
-
Page/Page column 62-63
(2012/01/13)
-
- New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity
-
A series of 3- and 5-aryl-1,2,4-oxadiazole derivatives were prepared and tested for anticonvulsant activity in a variety of models. These 1,2,4-oxadiazoles exhibit considerable activity in both pentylenetetrazole (PTZ) and maximal electroshock seizure (MES) models. Compound 10 was protective in the PTZ model in rats with an oral ED50 of 25.5 mg/kg and in the MES model in rats with an oral ED50 of 14.6 mg/kg. Neurotoxicity (rotarod) was observed with an ED50 of 335 mg/kg. We found several oxadiazoles that acted as selective GABA potentiating compounds with no interaction to the benzodiazepine binding site.
- Lankau, Hans-Joachim,Unverferth, Klaus,Grunwald, Christian,Hartenhauer, Helge,Heinecke, Kristina,Bernoester, Katrin,Dost, Rita,Egerland, Ute,Rundfeldt, Chris
-
p. 873 - 879
(2008/02/12)
-
- The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma
-
Adenosine has been suggested to play a role in asthma, possibly via activation of A2B adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A2B AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A2B AdoR antagonist with good selectivity (A2B AdoR Ki = 50 nM, selectivity A1 > 200: A2A > 200: A3 > 167).
- Zablocki, Jeff,Kalla, Rao,Perry, Thao,Palle, Venkata,Varkhedkar, Vaibhav,Xiao, Dengming,Piscopio, Anthony,Maa, Tenning,Gimbel, Art,Hao, Jia,Chu, Nancy,Leung, Kwan,Zeng, Dewan
-
p. 609 - 612
(2007/10/03)
-
- Substituted heterocyclic compounds
-
Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
- -
-
-
- NEW COMPOUNDS
-
The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
- -
-
Page/Page column 46
(2010/11/30)
-
- NEW COMPOUNDS
-
The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
- -
-
-
- CVT-4325: A potent fatty acid oxidation inhibitor with favorable oral bioavailability
-
New inhibitors of palmitoyl-CoA oxidation are based on the introduction of nitrogen heterocycles in the 'Western Portion' of the molecule. SAR studies led to the discovery of CVT-4325, a potent FOXi (IC50 = 380 nM, rat mitochondria) with favorable PK properties (F = 93%, t1/2 = 13.6 h, dog). New inhibitors of palmitoyl-CoA oxidation are based on the introduction of nitrogen heterocycles in the 'Western Portion' of the molecule. SAR studies led to the discovery of CVT-4325 (shown), a potent FOXi (IC50 = 380 nM rat mitochondria) with favorable PK properties (F = 93%, t1/2 = 13.6 h, dog).
- Elzein, Elfatih,Ibrahim, Prabha,Koltun, Dmitry O.,Rehder, Ken,Shenk, Kevin D.,Marquart, Timothy A.,Jiang, Bob,Li, Xiaofen,Natero, Reina,Li, Yuan,Nguyen, Marie,Kerwar, Suresh,Chu, Nancy,Soohoo, Daniel,Hao, Jia,Maydanik, Victoria Y.,Lustig, David A.,Zeng, Dewan,Leung, Kwan,Zablocki, Jeff A.
-
p. 6017 - 6021
(2007/10/03)
-